Brind.

89bio, a San Francisco-based company, is developing therapies for MASH and utilizes LinkedIn for information.

1 report, 1 independent Updated Jul 10

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

89bio mash

Keep exploring

The entities involved

89bio
Nothing else this week.
mash
fast genome and metagenome distance estimation using MinHash
- Wave Life Sciences is developing WVE-007, an investigational GalNAc-siRNA product, for MASH indications.Wed 12:44

Related events

INVENTIVA, a company focusing on MASH therapies, held leadership conferences in New York City and Brussels.Jun 7

Coverage

Newest first; wire copies grouped

Jul 10GlobeNewswire89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biophar